Generic placeholder image

Recent Patents on CNS Drug Discovery (Discontinued)


ISSN (Print): 1574-8898
ISSN (Online): 2212-3954

Antisense Oligonucleotides in the Treatment of Cerebral Gliomas. Review of Concerning Patents

Author(s): Gerardo Caruso and Maria Caffo

Volume 9, Issue 1, 2014

Page: [2 - 12] Pages: 11

DOI: 10.2174/1574889809666140307113439

Price: $65


Gliomas are the most common and malignant primary brain tumors in the adult population. Despite the intensive research on cancer pathology, real mechanisms concerning glioma progression are not completely understood. The prognosis in patients affected by malignant gliomas is still very unfavorable. Recent genomic analyses have revealed patterns of molecular changes within tumor subclasses that harbor distinct underlying biology, clinical prognosis, and pathogenic routes. So, novel treatments will have to be able to interfere at different molecular levels in gliomagenesis minimizing the toxicity. In particular, antisense oligonucleotides are able to inhibit expression of specific genes by interfering with transcription or, more usually, with translation.

In this review, we will focus on mechanisms of antisense oligonucleotides reporting clinical and experimental studies. We will also report a large number of patents which adopt the antisense oligonucleotides as potential therapeutic approach in gliomas treatment.

Keywords: Angiogenesis, antisense oligonucleotides, apoptosis, gliomas.

Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy